|
Home>Homoeopathy>Homoeoprophylaxis
(HP)
Parents are encouraged to make informed decisions, based
on information gained from a wide variety of sources, as to the best choice
of disease prevention for themselves and their dependants.
Three good starting points for research are:-
http://www.avn.org.au
http://immunise.health.gov.au/handbook.htm
Vaccination?
A Review of Risks and Alternatives 6th Edition, 2005, by
Isaac Golden
Homoeoprophylaxis (HP)
is the use of homoeopathically prepared substances to prevent targeted
diseases in recipients. It’s first use, in an epidemic of Scarlet Fever, was
documented in 1801. It has been used throughout the world since then for
both short term and long term preventative purposes. Since then there has
been significant clinical experience in the use of HP for disease prevention
however public health authorities do not except this evidence as proof of
efficacy.
The term
“homoeopathic vaccination” is a misnomer. Vaccination, a
well-understood medical term, relies on antibody formation. Homoeopathic
medicines do not rely on antibody formation. They affect the patient’s
initial predisposition to an illness, rather than the antibody/antigen
reaction.
Two
large studies were conducted in Brazil :-
-
In 1974
during an epidemic of meningitis, 18,640 children were treated
homoeoprophylactically and 6,340 were not. In the treated group four
cases of meningitis were reported, in the untreated group, 32 cases were
reported (Eizayaga, F.X. Treatise on Homeopathic Medicine.282-286,
E Marecel, Buenos Aires). Based on the attack rate in the
unprotected group, 94 cases would have been expected in the
homoeopathically protected group, had the remedies been ineffective.
-
On the
basis of this, in 1998 in Blumenau, Brazil, a large-scale investigation
of the use of homoeoprophylaxis was undertaken in persons up to 20 years
of age. In the first six months of administration, the following results
were obtained: of the 65,826 protected homoeopathically, one case was
reported and of the 23,532 not protected, 7 cases were reported. A
12-month follow-up reported 3 cases in the protected group and 13 cases
in the unprotected group. Statistical analysis demonstrated a 95%
protection in children over six months and 91% protection in children
over 12 months. Mroninski, C., Adriano, E. & Mattos G. Meningococcin,
its protective effect against meningococcal disease, Homoeopathic
LINKS 14 (4): 230-4, Winter, 2001).
Australian studies
on homoeoprophylaxis (HP) have been undertaken by Australian homoeopath and
statistician, Isaac Golden PhD, as part of his Doctoral studies through
Swinburne University, Victoria. His findings include the statistical
analysis of a fifteen year clinical study of HP. This study found the
overall effectiveness of the HP program was 90.4% The thesis also included a
favourable analysis of chronic health problems (or lack thereof) in children
covered by the HP program. The study may be viewed at:-
http://adt.lib.swin.edu.au/uploads/approved/adt-VSWT20050228.150047/public/02whole.pdf)
|
